CURRICULUM VITAE

Univ.-Prof. Dr. Danilo Fliser

Current position

Professor of Medicine
Saarland University

Director
Department of Internal Medicine IV
Renal and Hypertensive Disease & Transplant Centre
Saarland University Medical Centre

Kirrberger Straße
66421 Homburg/Saar
Germany
Tel.: 06841– 16 15040
Fax: 08641 – 16 15454
Email: danilo.fliser@uks.eu

Universitätsklinikum
des Saarlandes

Academic Appointments

1990 - 1998	Research Fellow at the Division of Nephrology, Department of Internal Medicine, Ruperto-Carola University, Heidelberg (Germany)
1996	Research Fellow at the Department of Endocrinology and Metabolism, University of Virginia, Charlottesville (USA)
1997	Faculty Rank in Internal Medicine
1998 - 1999	Assistant Professor (Internal Medicine) at the Ruperto-Carola University, Heidelberg (Germany)
1999 - 2007	Associate Professor (Internal Medicine) at the Hannover Medical School, Hannover (Germany) Head of the Clinical Research Unit
2007 -	Professor of Medicine at the Saarland University Director of the Department of Internal Medicine IV - Renal and Hypertensive Disease & Transplant Centre Saarland University Medical Centre Homburg/Saar (Germany)

2016	Chair of the Scientific Committee of the 53rd ERA-EDTA annual congress in Vienna
2016 - 2018	ERA-EDTA Ordinary Council Member
2015 -	Member of the ***CKDOPPS*** Steering Committee
2017 - 2019	Chair of the Paper Selection Committee for the ERA-EDTA annual congress
2018 – 2024	***Renal Science Chair*** *of the European Renal Association-European Dialysis and Transplant Association (****ERA-EDTA****)*

Awards and Honors

1995	*Nils Alwall Prize*
2004	*Bernd Tersteegen Prize*
2005	*Franz Volhard Prize*
2015	*FERA*

Membership

National

German Society for Internal Medicine
German Hypertension Society
German Society for Nephrology

International

ERA-EDTA	European Renal Association-European Dialysis and Transplant Association
EUTox	European Study Group on Uremia Toxicity

Member of the „Editorial Board”

Der Nephrologe (***Managing Editor***)
Kidney International
Nephrology, Dialysis and Transplantation (***Theme Editor***)

Publications

- Original publications listed in PubMed **>360**
- Original publications **>100 times cited** **>70**
- **Hirsch Index** (Google scolar) **86**

Research publications with an impact factor >20

Schunk SJ, et al. The alarminin interleukin-1α mediates leukocyte adhesion in cardiorenal diseases.
Circulation 2021 [online ahead of print]

Speer T, et al. Lipoproteins in chronic kidney disease – from bench to bedside.
Eur Heart J 2021 [Online ahead of print]

Jankowski J, et al. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options.
Circulation 2021; 143: 1157-1172

Schunk SJ, et al. WNT-β-catenin signalling - a versatile player in kidney injury and repair.
Nat Rev Nephrol 2021; 17: 172-184

Schunk SJ, et al. Genetically-determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.
Eur Heart J 2021; 42: 1742-1756

Zewinger et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.
Nat Immunol 2020, 21: 30-41

Schunk SJ, et al. Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study.
Lancet 2019; 394: 488-496

Zewinger S, et al. Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
Lancet Diabetes Endocrinol 2017; 5: 534-543

Zewinger S, et al. Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease.
Eur Heart J 2017; 38: 1597-1607

Bauer L, et al. HDL-cholesterol efflux capacity and cardiovascular events in patients with chronic kidney disease.
J Am Coll Cardiol 2017; 69: 246-247

Zewinger S, et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk.
Eur Heart J 2015; 36: 3007-3016

Speer T, et al. Carbamylated low-density lipoprotein induces endothelial dysfunction.
Eur Heart J 2014; 35: 3021-3032

Speer T, et al. Abnormal High-Density Lipoprotein Induces Endothelial Dysfunction via Activation of Toll-Like Receptor-2.
Immunity 2013; 38: 754-768

Rogacev KS, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography.
J Am Coll Cardiol 2012; 60: 1512-1520

Seiler S, et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation.
Eur Heart J 2011; 32: 2688-2696

Rogacev KS, et al. $CD14^{++}16^{+}$ monocytes are independent predictors of cardiovascular outcome in patients with chronic kidney disease.
Eur Heart J 2011; 32: 84-92

Zawada AM, et al. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset.
Blood 2011; 118: e50-61

Rogacev KS, et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis.
Eur Heart J 2010; 31: 369-376

Sorrentino SA, et al. Oxidant stress impairs in vivo re-endothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: Restoriation by peroxisome proliferator-activator receptor-gama agonist rosiglitazone.
Circulation 2007; 116: 163-173

Landmesser U, et al. Simvastatin vs. Ezetimibe: Pleiotropic vs. lipid lowering effects on endothelial function and endothelial progenitor cells in humans.
Circulation 2005; 111: 2356-2363

Fliser D, et al; for the EUTOPIA investigators (European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis). Anti-inflammatory effects of angiotensin II subtype 1-receptor blockade in hypertensive patients with micro-inflammation.
Circulation 2004; 110: 1103-1107

Bahlmann FH, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure.
Circulation 2004; 110: 1006-1012

Kielstein JT, et al. Cardiovascular effects of systemic NO synthase inhibition with asymmetric dimethylarginine in humans.
Circulation 2004; 109: 172-177

Kielstein JT, et al. Asymmetric dimethylarginine (ADMA), renal perfusion and blood pressure in elderly subjects.
Circulation 2003; 107: 1891-1895

Bahlmann FH, et al. Erythropoietin regulates endothelial progenitor cells.
Blood 2003: 103: 921-926